1
|
Weide R, Feiten S, Waßmann C, Rendenbach B, Braun U, Burkhard O, Ehscheidt P, Schmidt M. Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care. Cancers (Basel) 2024; 16:1255. [PMID: 38610931 PMCID: PMC11011127 DOI: 10.3390/cancers16071255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Revised: 03/14/2024] [Accepted: 03/20/2024] [Indexed: 04/14/2024] Open
Abstract
Overall survival (OS) of patients with metastatic breast cancer (MBC) has improved within controlled clinical trials. Whether these advances translate into improved OS in routine care is controversial. We therefore analyzed retrospectively unselected female patients from five oncology group practices and one university outpatient clinic, whose initial diagnosis of MBC was between 1995 and 2022. A total of 1610 patients with a median age of 63 years (23-100) were evaluated. In all, 82.9% had hormone-receptor-positive disease, and 23.8% were HER2-positive. Evaluation in time cohorts by initial MBC diagnosis date showed a continuous prolongation of median OS from 31.6 months (0.5-237.3+) (1995-2000) to 48.4 months (0.4-61.1+) (2018-2022) (p = 0.003). Univariable analyses showed a significant dependence on the time cohort of diagnosis, metastatic status at initial diagnosis, age at metastasis, hormone and HER2 status, general condition, metastasis localization, and the number of affected organs. A multivariable analysis revealed a significant dependence of survival probability on receptor status, general condition, and number of metastatic sites, as well as the time between initial breast cancer diagnosis and the diagnosis date of MBC in months. In sum, OS of patients with MBC has improved continuously and significantly in routine care over the last 27 years.
Collapse
Affiliation(s)
- Rudolf Weide
- Praxis für Haematologie und Onkologie Koblenz, 56068 Koblenz, Germany
- Institut für Versorgungsforschung in der Onkologie, 56068 Koblenz, Germany;
| | - Stefan Feiten
- Institut für Versorgungsforschung in der Onkologie, 56068 Koblenz, Germany;
| | - Christina Waßmann
- Johannes Gutenberg-Universitaet Mainz, Universitaetsmedizin Mainz, 55131 Mainz, Germany
| | | | - Ute Braun
- Onkologische Schwerpunktpraxis Braun und Hünermund, 67061 Ludwigshafen, Germany;
| | | | | | - Marcus Schmidt
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitaetsmedizin Mainz, 55131 Mainz, Germany;
| |
Collapse
|
2
|
Lutz C, Feiten S, Chakupurakal G, Heymanns J, Thomalla J, van Roye C, Weide R. Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic. BMC Immunol 2023; 24:2. [PMID: 36631764 PMCID: PMC9833869 DOI: 10.1186/s12865-022-00536-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Accepted: 12/23/2022] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Patients with indolent B-cell non-Hodgkin lymphomas (B-NHLs) have an increased risk of infections which is caused by pathomechanisms of the diseases itself but also as a result of anti-tumor therapy. Especially the effects of anti-CD20 antibodies are well understood as these lead to decreased antibody production. Most studies regarding immunodeficiency in B-NHLs were conducted with multiple myeloma and chronic lymphocytic leukemia patients. As these studies not always represent the general population we collected and analyzed real world data from patients with indolent lymphomas and a control group (CG). RESULTS Patients with B-NHLs undergoing therapy or who were regularly monitored in a watch and wait approach had, over the time of one year, an increased rate of infections compared to the CG of 145 healthy volunteers (mean: 11.66 vs. 7.13 infections per 1000 days). Consistent with this finding B-NHL patients received more antibiotic treatment (mean: 11.17 vs. 6.27 days) and were more often hospitalized than persons from the CG (mean: 5.19 vs. 0.99 days per 1000 days). Lymphoma patients without immunodeficiency had a lower infection rate than patients with non-symptomatic and symptomatic immunodeficiency (mean: 10.91 vs. 12.07 and 12.36 per 1000 days). The number of infections differed statistically significant for the subgroups and CG (7.13 per 1000 days). Patients with symptomatic immunodeficiency were mostly treated with regular immunoglobulin substitutions and infection rates were comparable to those of patients with asymptomatic immunodeficiency. CONCLUSIONS Our data suggest the use of an approach with regular immune monitoring including the measurement of immunoglobulin levels and regular appointments for clinical assessment of all indolent lymphoma patients in order to identify patients with increased risk of infections. It also raises the question if patients with immunodeficiency should be treated more often with regular immunoglobulin substitution, but so far more studies are necessary to answer this question.
Collapse
Affiliation(s)
- Christoph Lutz
- Praxis für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068, Koblenz, Germany.
| | - Stefan Feiten
- grid.488965.eInstitut für Versorgungsforschung in der Onkologie, Koblenz, Germany
| | - Geothy Chakupurakal
- grid.477753.50000 0004 0560 2414Praxis für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| | - Jochen Heymanns
- grid.477753.50000 0004 0560 2414Praxis für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| | - Jörg Thomalla
- grid.477753.50000 0004 0560 2414Praxis für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| | - Christoph van Roye
- grid.477753.50000 0004 0560 2414Praxis für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| | - Rudolf Weide
- grid.477753.50000 0004 0560 2414Praxis für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| |
Collapse
|
3
|
Weide R, Thomalla J, van Roye C, Chakupurakal G, Heymanns J, Köppler H, Feiten S, Nickel JA, Schmidberger H, Theobald M, Lutz C. Curricular course for medical students at a hematology and oncology specialty practice, 2010-2022. GMS J Med Educ 2022; 39:Doc40. [PMID: 36310886 PMCID: PMC9585415 DOI: 10.3205/zma001561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Figures] [Subscribe] [Scholar Register] [Received: 09/06/2021] [Revised: 05/16/2022] [Accepted: 07/05/2022] [Indexed: 06/16/2023]
Abstract
Aim: For several years now, medical students have also been taught general practice at academic medical teaching practices. Specialty practices have not yet been included in the curricular education. Since 1998, we have conducted a block seminar in hematology twice per semester for eighth-semester medical students. This block seminar was offered from 1998-2001 to students at the Philipps University in Marburg and since 2001 to students at the Johannes Gutenberg University in Mainz. Since 2010 our block seminar has been part of the curriculum at the Johannes Gutenberg University. Method: Standardized course evaluation by students who had attended our block seminar between January 2010 and March 2022. Courses that were held virtually due to corona were not included in the analysis. The questionnaire used to evaluate courses in the medical degree program at the Johannes Gutenberg University served as the evaluation instrument. Results: Since 1998 more than 1,000 students have attended our seminar. The systematic evaluation of the course by 500 students who participated in the curricular, classroom-based seminar sessions since 2010 shows that the highest ratings possible are given for practical relevance, learning atmosphere, teaching and effectiveness. Conclusion: High quality in teaching curricular courses to medical students at a specialty practice is possible. Insights into the possibilities connected with working in the outpatient setting at a medical practice broadens students' experience. This teaching format facilitates external university instructors in terms of teaching and, at the same time, relieves the university in terms of staff and financial budget.
Collapse
Affiliation(s)
- Rudolf Weide
- Praxis für Hämatologie und Onkologie, Koblenz, Germany
| | - Jörg Thomalla
- Praxis für Hämatologie und Onkologie, Koblenz, Germany
| | | | | | | | | | - Stefan Feiten
- Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany
| | | | - Heinz Schmidberger
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - Matthias Theobald
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | | |
Collapse
|
4
|
Feiten S, Scholl I, Dünnebacke J, Schmidt M, Franzen A, Ernst W, Spaderna H, Weide R. Shared decision‐making in routine breast cancer care in Germany – a cross‐sectional study. Psychooncology 2022; 31:1120-1126. [DOI: 10.1002/pon.5898] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 01/28/2022] [Accepted: 02/02/2022] [Indexed: 12/09/2022]
Affiliation(s)
- Stefan Feiten
- Institut für Versorgungsforschung in der Onkologie Koblenz
| | - Isabelle Scholl
- Institut und Poliklinik für Medizinische Psychologie Universitätsklinikum Hamburg‐Eppendorf
| | - Jan Dünnebacke
- Brustzentrum Marienhof Katholisches Klinikum Koblenz‐Montabaur
| | - Marcus Schmidt
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz
| | - Arno Franzen
- Brustzentrum Kemperhof Gemeinschaftsklinikum Mittelrhein Koblenz
| | - Walter Ernst
- Brustzentrum St. Elisabeth Gemeinschaftsklinikum MittelrheinMayen
| | - Heike Spaderna
- Abteilung Gesundheitspsychologie Pflegewissenschaft Universität Trier
| | | |
Collapse
|
5
|
Kowalski C, Albert US, Baumann W, Carl EG, Ernstmann N, Hermes-Moll K, Fallenberg EM, Feick G, Feiten S, Härter M, Heidt V, Heuser C, Hübner J, Joos S, Katalinic A, Kempkens Ö, Kerek-Bodden H, Klinkhammer-Schalke M, Koller M, Langer T, Lehner B, Lux MP, Maatouk I, Pfaff H, Ratsch B, Schach S, Scholl I, Skoetz N, Voltz R, Wiskemann J, Inwald E. [DNVF Memorandum Health Services Research in Oncology]. Gesundheitswesen 2020; 82:e108-e121. [PMID: 32858754 DOI: 10.1055/a-1191-3759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Health services research in oncology deals with all situations which cancer patients face. It looks at the different phases of care, i. e. prevention / early detection, prehabilitation, diagnostics, therapy, rehabilitation and palliative care as well as the various actors, including those affected, the carers and self-help. It deals with healthy people (e. g. in the context of prevention / early detection), patients and cancer survivors. Due to the nature of cancer and the existing care structures, there are a number of specific contents for health services research in oncology compared to general health services research while the methods remain essentially identical. This memorandum describes the subject, illustrates the care structures and identifies areas of health services research in oncology. This memorandum has been prepared by the Oncology Section of the German Network for Health Services Research and is the result of intensive discussions.
Collapse
Affiliation(s)
| | | | - Walter Baumann
- Wissenschaftliches Institut der Niedergelassenen Hämatologen und Onkologen (WINHO GmbH), Köln
| | - Ernst-Günther Carl
- Haus der Krebsselbsthilfe, Bonn.,Bundesverband Prostatakrebs Selbsthilfe, Bonn
| | - Nicole Ernstmann
- Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Forschungsstelle für Gesundheitskommunikation und Versorgungsforschung, Universitätsklinikum Bonn, Bonn.,Zentrum für Integrierte Onkologie, Universitätsklinikum Bonn, Bonn.,Institut für Patientensicherheit, Universitätsklinikum Bonn, Bonn
| | - Kerstin Hermes-Moll
- Wissenschaftliches Institut der Niedergelassenen Hämatologen und Onkologen (WINHO GmbH), Köln
| | - Eva Maria Fallenberg
- Klinik und Poliklinik für Radiologie, Ludwig-Maximilians-Universität München, München
| | | | - Stefan Feiten
- Institut für Versorgungsforschung in der Onkologie GbR, Koblenz
| | - Martin Härter
- Zentrum für Psychosoziale Medizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - Vitali Heidt
- Wissenschaftliches Institut der Niedergelassenen Hämatologen und Onkologen (WINHO GmbH), Köln
| | - Christian Heuser
- Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Forschungsstelle für Gesundheitskommunikation und Versorgungsforschung, Universitätsklinikum Bonn, Bonn.,Zentrum für Integrierte Onkologie, Universitätsklinikum Bonn, Bonn
| | - Joachim Hübner
- Zentrum für Bevölkerungsmedizin und Versorgungsforschung, Universität zu Lübeck, Lübeck
| | - Stefanie Joos
- Institute of General Practice and Interprofessional Care, University of Tübingen Faculty of Science, Tübingen
| | - Alexander Katalinic
- Institut für Sozialmedizin und Epidemiologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck.,Institut für Krebsepidemiologie e.V., Universität zu Lübeck, Lübeck
| | | | | | - Monika Klinkhammer-Schalke
- Institut für Qualitätssicherung und Versorgungsforschung, Tumorzentrum Regensburg, Universität Regensburg, Regensburg.,Institut for Quality Assurance and Health Services Research, Tumorcenter Regensburg, University of Regensburg, Regensburg
| | - Michael Koller
- Zentrum für Klinische Studien, Universitätsklinikum Regensburg, Regensburg
| | | | - Burkhard Lehner
- Klinik für Orthopädie und Unfallchirurgie, Universitätsklinik Heidelberg, Heidelberg
| | - Michael P Lux
- Frauen- und Kinderklinik St. Louise, St. Vincenz-Krankenhaus, Paderborn
| | - Imad Maatouk
- Klinik für Allgemeine Innere Medizin und Psychosomatik, UniversitätsKlinikum Heidelberg, Heidelberg
| | | | - Boris Ratsch
- Market Access & Public Affairs, Takeda Pharma Vertrieb GmbH & Co KG, Berlin
| | | | - Isabelle Scholl
- Institut und Poliklinik für Medizinische Psychologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - Nicole Skoetz
- Zentrum für integrierte Onkologie, Universitätsklinik Köln
| | | | - Joachim Wiskemann
- Nationales Zentrum für Tumorerkrankungen Heidelberg, Heidelberg.,UniversitätsKlinikum Heidelberg, Heidelberg
| | - Elisabeth Inwald
- Klinik für Frauenheilkunde und Geburtshilfe, Universität Regensburg, Regensburg
| |
Collapse
|
6
|
Weide R, Schnell R, Schardt C, Koenigsmann M, Otremba B, Zahn MO, Wierecky J, Braun U, Hensel M, Klausmann M, Fleckenstein D, Ehscheidt P, Feiten S. Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement. BMC Immunol 2020; 21:39. [PMID: 32600256 PMCID: PMC7325170 DOI: 10.1186/s12865-020-00368-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Accepted: 06/17/2020] [Indexed: 11/16/2022] Open
Abstract
Background The effects of intravenous immunoglobulin G replacement on perceived health and infection susceptibility of patients suffering from immunoglobulin G (IgG) deficiencies should be evaluated in a prospective analysis. Methods Patients with symptomatic primary or secondary IgG deficiencies were interviewed prior to the first IgG infusion (t0) and over the course of their treatment (t1 - t6). The respondents rated their current health using a 100 point scale (EQ-5D-5L), ranging from 0 (‘worst imaginable health’) to 100 (‘best imaginable health’). The patients also provided information on the frequency of infections and of infections requiring antibiotics in the past 8 weeks. A healthy control group (CG) without oncologic diseases answered the questions once. Results One hundred six patients with a median age of 65 years (21–85 years) were investigated. The median serum IgG concentration changed from 500 mg/dl (t0) to 772 mg/dl (t6). The mean number of infections and of infections requiring antibiotics decreased during IgG replacement significantly. Current health according to EQ-5D-5L improved from 57 (t0) to 68 (t6), compared to 73 in the CG. Conclusion During the course of IgG replacement patients reported fewer and less severe infections. Their health assessment improved but still was inferior to the healthy CG.
Collapse
Affiliation(s)
- Rudolf Weide
- Praxis für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068, Koblenz, Germany.
| | - Roland Schnell
- pioh - Praxis Internistischer Onkologie und Hämatologie, Frechen, Germany
| | - Christof Schardt
- Onkologische Gemeinschaftspraxis und Tagesklinik, Gelsenkirchen, Germany
| | | | | | | | - Jan Wierecky
- Überörtliche Gemeinschaftspraxis, Dres. Verpoort, Wierecky & Brandl, Schwerpunkt Onkologie & Hämatologie, Hamburg, Germany
| | - Ute Braun
- Gemeinschaftspraxis für Hämatologie und Onkologie, Ludwigshafen, Germany
| | | | | | | | | | - Stefan Feiten
- Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany
| |
Collapse
|
7
|
Weide R, Feiten S, Chakupurakal G, Friesenhahn V, Kleboth K, Köppler H, Lutschkin J, van Roye C, Thomalla J, Heymanns J. Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017. Leuk Lymphoma 2019; 61:557-566. [PMID: 31682164 DOI: 10.1080/10428194.2019.1680840] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Seven hundred and twenty-four CLL-outpatients with a median age of 67 (35-92) were analyzed. Four hundred and twenty-seven (59%) were male, 297 (41%) female. At diagnosis 556 (77%) were in Binet stage A, 91 (13%) stage B and 36 (5%) stage C. Forty-six percent received treatment during the evaluation period. Treatment consisted of purine analogs in 38%, alkylating agents in 96%, chemoimmunotherapy with anti-CD20 monoclonal antibodies in 63%, ibrutinib in 9%, venetoclax in 1% and idelalisib in 3%. 3% received allogeneic hematopoietic stem cell transplantation. Overall survival (OS) according to Binet stage was: A 13.9 years (0.1-37.4), B 9.2 years (1.4-29.3) and C 7.9 years (0.5-19.4) respectively. Median OS from the start of therapy improved over time; 1995-2001: 5.8 years, 2002-2008: 6.1 years and 2009-2017: median not reached. Survival of patients with CLL has improved in routine care and was strongly related to active disease, disease stage, performance status and whether therapy included an anti-CD20 monoclonal antibody.
Collapse
Affiliation(s)
- Rudolf Weide
- Praxis für Hämatologie und Onkologie, Koblenz, Germany
| | - Stefan Feiten
- Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany
| | | | - Vera Friesenhahn
- Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany
| | - Kristina Kleboth
- Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany
| | | | - Julia Lutschkin
- Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany
| | | | - Jörg Thomalla
- Praxis für Hämatologie und Onkologie, Koblenz, Germany
| | | |
Collapse
|
8
|
Weide R, Chakupurakal G, Feiten S, Friesenhahn V, Kleboth K, Koeppler H, Lutschkin J, Thomalla J, van Roye C, Burkhard O, Reiser M, Ehscheidt P, Heymanns J. Survival of patients with advanced solid tumors who receive treatment in community based oncology group practices is comparable to randomized controlled trials (RCT). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e18770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Rudolf Weide
- Joint Practice for Hematology and Oncology, Koblenz, Germany
| | | | - Stefan Feiten
- Institut fuer Versorgungsforschung in der Onkologie, Koblenz, Germany
| | - Vera Friesenhahn
- Institut fuer Versorgungsforschung in der Onkologie, Koblenz, Germany
| | - Kristina Kleboth
- Institut fuer Versorgungsforschung in der Onkologie, Koblenz, Germany
| | - Hubert Koeppler
- Praxisklinik fuer Haematologie und Onkologie, Koblenz, Germany
| | - Julia Lutschkin
- Institut fuer Versorgungsforschung in der Onkologie, Koblenz, Germany
| | - Jörg Thomalla
- Praxisklinik fuer Haematologie und Onkologie, Koblenz, Germany
| | | | - Oswald Burkhard
- Internistische Gemeinschaftspraxis Haematologie, Onkologie, Palliativmedizin, Worms, Germany
| | - Marcel Reiser
- PIOH - Praxis Internistische Onkologie und Haematologie, Cologne, Germany
| | | | - Jochen Heymanns
- Praxisklinik fuer Haematologie und Onkologie, Koblenz, Germany
| |
Collapse
|
9
|
Feiten S, Scholl I, Schmidt M, Dünnebacke J, Franzen A, Ernst W, Weide R. Abstract P4-11-07: Shared decision making (SDM) in routine care treatment of breast cancer patients – a survey of patients following surgery. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The aim of shared decision making (SDM), defined as an interaction between patient and attending physician(s), is a treatment decision in which patients are meaningfully involved. Based on mutual agreement and active participation the awareness of a choice should be created and the choice respected. Many preference-sensitive decisions have to be made in breast cancer treatment. However, little is known about the implementation of SDM in German breast cancer care. We therefore investigated the process of SDM from the patients' perspective.
Methods: All breast cancer patients who underwent surgery in one of four certified breast cancer centers in Germany between 07/2016 and 12/2016 were invited by mail to participate in the survey. The experienced decision-making process was assessed using the 9-item Shared Decision Making Questionnaire (SDM-Q-9). SDM-Q-9 items were rated on a 6-point scale ranging from "completely disagree" to "completely agree", added together and transformed into a scale ranging from 0 to 100. The higher the total score the higher the experienced degree of participation in the decision-making process. The survey also assessed patients' satisfaction with treatment, satisfaction with decisions and decisional control preferences, and included a range of demographic and clinical questions. For most items we asked the participants to separately rate decision-making consultations with their inpatient hospital doctors, outpatient gynecologists, outpatient oncologists and primary care providers (PCP). The project is still ongoing, data of approximately 300 patients will be presented at the meeting in December.
Results: Of 289 patients approached by mail, 143 filled in the survey (response rate: 49%). Median age at the time of the survey was 62 years (36-89). 83% had breast conserving surgery, 17% mastectomy. 74% were treated with radiation, 31% received neo-/adjuvant chemotherapy. 14% were off-treatment at the time of survey participation, 67% still received antihormonal therapy, 9% anti HER2 treatment, 7% chemotherapy and 2% radiation. Inpatient hospital doctors achieved the highest SDM-Q-9 score (mean of 75, standard deviation of 22) indicating the highest degree of SDM. Oncologists, gynecologists and PCP were rated quite comparable with a mean score of 72 each and standard deviations (SD) of 27, 22 and 31. The mean score for all groups of doctors was 73. For items concerning satisfaction with quality and amount of doctors' information and participation in medical decisions patients showed a high degree of satisfaction, resulting in mean values of 3.6 and 3.5 with SD of 0.6 on a 4-point scale ranging from "1" "very unsatisfied" to "4" "very satisfied".
Conclusions: A considerable number of patients took part in the survey. Overall, patients reported to have experienced SDM in many situations where treatment decisions were necessary. Patients were quite satisfied with the quality of information and their participation in medical decisions. However, we do not know whether non-respondents might have had different experiences regarding their treatment decision-making. Further research should include SDM expert observations of breast cancer treatment decisions to validate these findings.
Citation Format: Feiten S, Scholl I, Schmidt M, Dünnebacke J, Franzen A, Ernst W, Weide R. Shared decision making (SDM) in routine care treatment of breast cancer patients – a survey of patients following surgery [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-11-07.
Collapse
Affiliation(s)
- S Feiten
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - I Scholl
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - M Schmidt
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - J Dünnebacke
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - A Franzen
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - W Ernst
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| | - R Weide
- Institute for Health Services Research in Oncology, Koblenz, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University of Mainz Medical School, Mainz, Germany; Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz, Germany; Breast Cancer Center Kemperhof, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany; Breast Cancer Center St. Elisabeth, Gemeinschaftsklinikum Mittelrhein, Mayen, Germany; Hematology/Oncology Group Practice, Koblenz, Germany
| |
Collapse
|
10
|
Chakupurakal G, Feiten S, Burkhard O, Reiser M, Ehscheidt P, Weide R. Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices. Oncol Res Treat 2017; 40:784-788. [PMID: 29183029 DOI: 10.1159/000480016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Accepted: 08/04/2017] [Indexed: 12/30/2022]
Abstract
BACKGROUND Randomized clinical trials do not reflect the day-to-day reality of patient care; hence, the treatment of patients with advanced pancreatic cancer in oncology group practices was evaluated. PATIENTS AND METHODS All consecutive patients with advanced pancreatic cancer who were treated between 01/2012 and 12/2015 in 4 oncology group practices were analyzed retrospectively using SPSS software. RESULTS 324 patients with a median age of 70 years (range 32-94 years) were analyzed. The majority were male (56%) and had distant metastases (74%). Chemotherapy was the major modality of treatment (86%) with a median overall survival (OS) of 33.3 weeks (range 1.7-245.4 weeks). Chemotherapy significantly (p < 0.001) improved OS in comparison to best supportive care only (37.6 vs. 13.9 weeks). Patients with locally advanced disease had a better prognosis compared to patients with metastases (median OS 49.6 vs. 30.4 weeks; p < 0.001). An age-adjusted Charlson comorbidity score of ≥ 9 was found to influence the OS significantly (p = 0.004). CONCLUSION Chemotherapy remains the main modality of treatment for patients with advanced pancreatic cancer with an OS comparable to prospective randomized trials. The OS of this patient cohort has remained the same over the last 20 years despite advances in treatment modalities.
Collapse
|
11
|
Feiten S, Dünnebacke J, Friesenhahn V, Heymanns J, Köppler H, Meister R, Thomalla J, van Roye C, Wey D, Weide R. Follow-up Reality for Breast Cancer Patients - Standardised Survey of Patients and Physicians and Analysis of Treatment Data. Geburtshilfe Frauenheilkd 2016; 76:557-563. [PMID: 27239065 DOI: 10.1055/s-0042-106210] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Introduction: Currently, about 360 000 breast cancer patients who could, after completion of their primary therapy, take advantage of follow-up options are living in Germany. Up to now very little is known about the extent to which the available options are used and as to how the follow-up reality is experienced and evaluated. Thus, an explorative examination among the patients and their physicians was undertaken. Patients and Methods: All patients who underwent surgery in a certified breast centre between 2007 and 2013 received a standardised questionnaire; at the same time the physicians responsible for the follow-up were invited to answer a standardised questionnaire. Results: 920 patients (response rate: 61 %) with a median age of 65 years (32-95) could be analysed. 99 % of the participants stated that they regularly attended follow-ups. The personal contact with the physician (mean value: 4.4) and the reassurance that the cancer disease had not recurred (mean value: 4.5) were described on a scale of 0 to 5 to be two of the most important factors of the follow-up. Deficits were expressed with regard to psychosocial care (70 %) and the perception and treatment of physical complaints (55 %). In addition, 105 physicians returned completed questionnaires (response rate: 12 %). For asymptomatic patients the physicians performed the following examinations most frequently: anamnesis (92 %), physical examination (87 %) as well as laboratory tests (63 %) and tumour marker determinations (40 %). Conclusion: On the whole it became clear that the vast majority of the patients took advantage of the follow-up options. From the patient's perspective the importance of the follow-up lies in contact to the physician and the comforting assurance that the breast cancer has not relapsed. Deficits are seen in the psychosocial care and the perception and treatment of physical impairments. Not recommended examinations were employed by a significant proportion of the surveyed physicians.
Collapse
Affiliation(s)
- S Feiten
- Institut für Versorgungsforschung in der Onkologie, Koblenz
| | - J Dünnebacke
- Brustzentrum im Marienhof, Katholisches Klinikum Koblenz-Montabaur, Koblenz
| | - V Friesenhahn
- Institut für Versorgungsforschung in der Onkologie, Koblenz
| | - J Heymanns
- Praxisklinik für Hämatologie und Onkologie, Koblenz
| | - H Köppler
- Praxisklinik für Hämatologie und Onkologie, Koblenz
| | - R Meister
- Institut für Versorgungsforschung in der Onkologie, Koblenz
| | - J Thomalla
- Praxisklinik für Hämatologie und Onkologie, Koblenz
| | - C van Roye
- Praxisklinik für Hämatologie und Onkologie, Koblenz
| | - D Wey
- Brustzentrum im Marienhof, Katholisches Klinikum Koblenz-Montabaur, Koblenz
| | - R Weide
- Praxisklinik für Hämatologie und Onkologie, Koblenz
| |
Collapse
|
12
|
Feiten S, Weide R, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, van Roye C, Thomalla J. Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice. Springerplus 2016; 5:270. [PMID: 27006879 PMCID: PMC4777967 DOI: 10.1186/s40064-016-1851-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Accepted: 02/15/2016] [Indexed: 12/18/2022]
Abstract
Due to the increase of oral agents nonadherence is an emerging challenge in cancer care. We evaluated how well different assessments match and how adherence could be measured in routine care. For this purpose patients suffering from metastatic solid tumors who were treated with oral anticancer drugs in an oncology group practice were surveyed. Attending oncologists answered a questionnaire, too, and a retrospective analysis of prescription data was conducted. Caregivers who were eligible for an interview were surveyed additionally. 128 patients (70 % female) with a median age of 69 years (36-88) took part, 95 % of all approached patients. 56 % suffered from metastatic breast cancer, 44 % from other metastatic solid tumors. 65 caregivers (60 % female) with a median age of 62 years (21-82) were interviewed as well. Patients were assessed in 84 % as very reliable in medication-taking by their oncologists. This high adherence rate was supported by patients, caregivers and prescription data. However, concordance between assessments of patients, caregivers and oncologists was not substantial. Our method of considering different perspectives to assess adherence has to be improved and validated but could help to evaluate adherence with oral cancer therapy in routine care.
Collapse
Affiliation(s)
- Stefan Feiten
- Institut für Versorgungsforschung in der Onkologie, Neversstr. 5, 56068 Koblenz, Germany
| | - Rudolf Weide
- Praxisklinik für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| | - Vera Friesenhahn
- Institut für Versorgungsforschung in der Onkologie, Neversstr. 5, 56068 Koblenz, Germany
| | - Jochen Heymanns
- Praxisklinik für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| | - Kristina Kleboth
- Institut für Versorgungsforschung in der Onkologie, Neversstr. 5, 56068 Koblenz, Germany
| | - Hubert Köppler
- Praxisklinik für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| | - Christoph van Roye
- Praxisklinik für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| | - Jörg Thomalla
- Praxisklinik für Hämatologie und Onkologie Koblenz, Neversstr. 5, 56068 Koblenz, Germany
| |
Collapse
|
13
|
Weide R, Feiten S, Friesenhahn V, Heymanns J, Köppler H, Meister R, van Roye C, Thomalla J, Wey D, Dünnebacke J. Abstract P4-10-13: Follow-up care of breast cancer patients who were treated in a German breast cancer centre - Survey of patients and attending physicians and analysis of treatment data. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-10-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Breast cancer treatment leads to long-lasting impairments which, according to international guidelines, have to be identified and treated in follow-up care. It remains unclear how follow-up care is perceived by patients and if all needs are met in routine care.
Methods: All breast cancer patients who underwent surgery in a German breast cancer centre from 2007 to 2013 were asked to fill out a standardized scanner-readable questionnaire. Medical data were retrieved from their charts and statistically analyzed together with the questionnaire responses. Physicians who could possibly care for breast cancer patients after primary therapy were invited to fill out a standardized scanner-readable questionnaire as well.
Results: 920 questionnaires were filled out and returned (response rate: 61%) by patients. Median age at the time of the survey was 65 years (32-95). 58% of patients still received some form of therapy, 94% of them hormonal therapy. 94% were still in follow-up care, 5% stopped and 1% never went. Intervals of follow-up visits suggested by international guidelines were assessed as "quite right" in 93%. The following examinations were conducted throughout the whole follow-up period at least once: physical examination (93%), mammography (90%), sonography of breast (81%) and liver (22%), laboratory (56%), tumor marker (23%), bone scan (21%), MRI (20%) and CT (15%). Different items were rated on a 6-point scale ranging from "0" "not true at all" to "5" "completely true". Follow-up care was regarded as very important for the own health (4.7), reassuring and calming (4.5), well-being to be looked after (4.4) and well cared for (4.4). A continuous contact between patient and doctor was appreciated (4.4). Visits were connected only to a part with distress (2.1), the median score on the NCCN distress thermometer was 4 (0-10).
105 questionnaires were answered by healthcare professionals (response rate 12%), most of them general practitioners (51%) or gynecologists (30%). Doctors carried out or referred asymptomatic patients most often to the following examinations: medical history taking (92%), physical examination (87%), blood chemistry (63%) and tumor markers (40%). Mammography was mentioned in 45%, sonographic examinations of breast, liver and axilla in 49%, 45% and 38%, respectively. 55% were (very) satisfied with international guidelines on follow-up care. Intervals and duration of follow-up visits were assessed as "quite right" in 88% and 60%, respectively. Different items were rated on a 6-point scale ranging from "0" "not important at all" to "5" "very important". Detection of disease recurrence and secondary tumors (4.8), reassurance of patients (4.7) and detection of treatment toxicities (4.5) were assessed as most important aims in follow-up care.
Conclusions: An overwhelming majority of patients makes use of follow-up care. Most important qualities from the patient's perspective are reassurance, a feeling of security, calming and continuous care by their doctor. Examinations which are not recommended in international guidelines are used by a considerable amount of healthcare providers.
Citation Format: Weide R, Feiten S, Friesenhahn V, Heymanns J, Köppler H, Meister R, van Roye C, Thomalla J, Wey D, Dünnebacke J. Follow-up care of breast cancer patients who were treated in a German breast cancer centre - Survey of patients and attending physicians and analysis of treatment data. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-10-13.
Collapse
Affiliation(s)
- R Weide
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| | - S Feiten
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| | - V Friesenhahn
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| | - J Heymanns
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| | - H Köppler
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| | - R Meister
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| | - C van Roye
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| | - J Thomalla
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| | - D Wey
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| | - J Dünnebacke
- Hematology/Oncology Group Practice, Koblenz, Germany; Institute for Healthcare Research in Oncology, Koblenz, Germany; Breast Cancer Center Marienhof, Koblenz, Germany
| |
Collapse
|
14
|
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H. Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014. Oncol Res Treat 2015; 39:41-4. [DOI: 10.1159/000442769] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Accepted: 11/11/2015] [Indexed: 11/19/2022]
|
15
|
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H. [Immunoglobulin substitution in patients with indolent non-Hodgkin's lymphoma]. Dtsch Med Wochenschr 2015; 140:e201-6. [PMID: 26402188 DOI: 10.1055/s-0041-102631] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND Infections are major complications in chronic lymphoproliferative disorders, among them indolent non-Hodgkin's lymphoma (iNHL) including chronic lymphocytic leukemia, follicular lymphoma and multiple myeloma.We report on a retrospective cohort analysis of outpatients with indolent non-Hodgkin's lymphoma who were treated in an oncology / hematology group practice and received intravenous polyvalent immunoglobulin G (IVIG) as supportive care. The aim was to describe the treated iNHL population, the course of therapy and the effects of IVIG administrations on the levels of immunoglobulin G (IgG), the incidence of infections and the survival time. PATIENTS AND METHOD 57 patients with secondary iNHL antibody deficiencies (n = 46) or IgG subclass deficiencies (n = 11) who received IVIG substitution were included. Patients received median 11 IVIG doses with a mean dose of 28 g over a period of median 9.5 months. RESULTS Mean IgG levels increased with IVIG substitution at about twice and then remained within the normal range. The incidence of infections decreased in 46 % of treated patients. Effects on survival could not be observed. Median overall survival was in the group of substituted patients 124 months (range 7-124), the control group had a median survival time of 96 months (range 3-129) (p = 0.537). CONCLUSION IgG levels should be reviewed during IVIG substitution on a regular basis and dosage and intervals should be adjusted individually.
Collapse
Affiliation(s)
- R Weide
- Praxisklinik für Hämatologie und Onkologie Koblenz
| | - S Feiten
- Institut für Versorgungsforschung in der Onkologie (InVO), Koblenz
| | - V Friesenhahn
- Institut für Versorgungsforschung in der Onkologie (InVO), Koblenz
| | - J Heymanns
- Praxisklinik für Hämatologie und Onkologie Koblenz
| | - K Kleboth
- Institut für Versorgungsforschung in der Onkologie (InVO), Koblenz
| | - J Thomalla
- Praxisklinik für Hämatologie und Onkologie Koblenz
| | - C van Roye
- Praxisklinik für Hämatologie und Onkologie Koblenz
| | - H Köppler
- Praxisklinik für Hämatologie und Onkologie Koblenz
| |
Collapse
|
16
|
Feiten S, Dünnebacke J, Friesenhahn V, Heymanns J, Koeppler H, Meister R, van Roye C, Thomalla J, Wey D, Weide R. Follow-up care of breast cancer survivors: Survey of patients and analysis of treatment data in a German breast cancer centre. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e20602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Stefan Feiten
- Institute for Healthcare Research in Oncology, Koblenz, Germany
| | - Jan Dünnebacke
- Breast Cancer Centre Marienhof, Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany
| | | | | | | | - Rebecca Meister
- Institute for Healthcare Research in Oncology, Koblenz, Germany
| | | | - Jörg Thomalla
- Hematology and Oncology Group Practice, Koblenz, Germany
| | - Diana Wey
- Breast Cancer Centre Marienhof, Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany
| | - Rudolf Weide
- Hematology and Oncology Group Practice, Koblenz, Germany
| |
Collapse
|
17
|
Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R. Breast cancer morbidity: questionnaire survey of patients on the long term effects of disease and adjuvant therapy. Dtsch Arztebl Int 2015; 111:537-44. [PMID: 25145512 DOI: 10.3238/arztebl.2014.0537] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Revised: 03/05/2014] [Accepted: 05/28/2014] [Indexed: 11/27/2022]
Abstract
BACKGROUND Many women have symptoms of various kinds after being treated for breast cancer. It is unclear how frequently these different side effects of treatment arise. METHOD All women who underwent surgery for breast cancer and subsequently received adjuvant systemic treatment in a single certified breast-cancer center from 2006 to 2010 were asked to fill out a standardized questionnaire. Medical data were retrieved from their charts and statistically analyzed together with the questionnaire responses. The questionnaire was also given to an age-adjusted control group. RESULTS 734 questionnaires were filled out and returned (response rate, 70%). The mean interval from the diagnosis of breast cancer to the time of response to the questionnaire was 38 months. The median age at time of response to the questionnaire was 65 years (range, 30 to 91 years). The distribution of UICC stages at the time of initial diagnosis was as follows: I 46%, II 42%, III 12%. 78% of the patients underwent breat conserving surgery, 85% had radio - therapy, 85% had antihormonal treatment, and 49% had chemotherapy. 91% were satisfied or very satisfied with the outcome of surgery. 34% reported operation site pain; 35% reported limitations of shoulder or arm function. Younger patients suffered from emotional sequelae more than older ones did. 25% reported a change in their relationship with their spouse. Before being diagnosed with breast cancer, 9% had consulted a psychiatrist or psychotherapist; after the diagnosis, 19% did. 14% had taken psychoactive medication before the diagnosis, and 26% did afterward. CONCLUSION Treatment for breast cancer has negative physical, emotional, and social effects on many patients. They suffer these effects to varying degrees depending on age, type of surgery, and systemic treatment.
Collapse
Affiliation(s)
- Stefan Feiten
- Institute for Health Services Research in Oncology (InVO), Koblenz
| | - Jan Dünnebacke
- Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz
| | | | | | - Jörg Thomalla
- Outpatient Clinic for Hematology and Oncology, Koblenz
| | | | - Diana Wey
- Breast Cancer Center Marienhof, Catholic Clinical Center Koblenz-Montabaur, Koblenz
| | - Rudolf Weide
- Outpatient Clinic for Hematology and Oncology, Koblenz
| |
Collapse
|
18
|
Feiten S, Dünnebacke J, Weide R. In reply. Dtsch Arztebl Int 2015; 112:176. [PMID: 25837747 DOI: 10.3238/arztebl.2015.0176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus 2014; 3:535. [PMID: 25279326 PMCID: PMC4177050 DOI: 10.1186/2193-1801-3-535] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Accepted: 09/12/2014] [Indexed: 01/23/2023]
Abstract
18,000 women die due to metastatic breast cancer in Germany per year. Median survival is 20–28 months after diagnosis. The question we wanted to answer was whether survival has improved in routine care? For this purpose we conducted a retrospective analysis of all patients with metastatic breast cancer who were treated between 06/1995-06/2013 in a community-based oncology group practice in Germany. 716 patients were analyzed with a median age of 61 (31–93). Localizations of metastases were distributed as follows: 47% visceral, 36% bone, 9% lymphatic, 4% CNS, 4% others. 79% were hormone-receptor-positive, 20% Her2-positive, 9% triple-negative. Median overall survival was 34 months (95% Confidence Interval: 31–37), median disease-specific survival 36.8 months and disease-specific survival after 5 years 34%. Survival was significantly correlated with localizations of metastases, number of metastasized organs, disease free survival since initial diagnosis, hormone-receptor status and age. Patients with hormone-receptor-positive tumors had a median overall survival of 37 months, Her2-positive patients of 34 months and triple-negative patients of 13 months. 86% of hormone-receptor-positive patients received antihormonal therapy. 81% of Her2-positive patients received anti-Her2 therapy. In summary, longer survival is strongly restricted to hormone receptor- and Her2-positive tumors most likely due to targeted therapies directed against the estrogen-receptor and Her2.
Collapse
Affiliation(s)
- Rudolf Weide
- Praxisklinik für Hämatologie und Onkologie, Neverstr. 5, 56068 Koblenz, Germany
| | - Stefan Feiten
- Institut für Versorgungsforschung in der Onkologie, Neverstr. 5, 56068 Koblenz, Germany
| | - Vera Friesenhahn
- Institut für Versorgungsforschung in der Onkologie, Neverstr. 5, 56068 Koblenz, Germany
| | - Jochen Heymanns
- Praxisklinik für Hämatologie und Onkologie, Neverstr. 5, 56068 Koblenz, Germany
| | - Kristina Kleboth
- Institut für Versorgungsforschung in der Onkologie, Neverstr. 5, 56068 Koblenz, Germany
| | - Jörg Thomalla
- Praxisklinik für Hämatologie und Onkologie, Neverstr. 5, 56068 Koblenz, Germany
| | - Christoph van Roye
- Praxisklinik für Hämatologie und Onkologie, Neverstr. 5, 56068 Koblenz, Germany
| | - Hubert Köppler
- Praxisklinik für Hämatologie und Onkologie, Neverstr. 5, 56068 Koblenz, Germany
| |
Collapse
|
20
|
Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R. Abstract P6-08-08: Adjuvant breast cancer therapy: Correlation of treatment data with patient reported outcomes in a German breast cancer centre. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-08-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: Clinical diagnosis and treatment data lack a subjective perspective of the affected patients. Patient reported outcomes on the other hand often provide only basic information of the medical background. In this analysis we matched treatment data from clinical files and subjective experiences of breast cancer patients.
Methods: Identification of breast cancer patients who had their primary surgery between 2006 and 2010 at a breast cancer centre followed by systemic adjuvant treatment. Relevant medical data were transferred from clinical files into a database and patients were asked to fill in a standardized paper pencil interview. Statistical analyses were conducted using SPSS 19.
Results: 1044 unselected female patients who suffered from invasive breast cancer were contacted, 740 responded (return rate 70.9%) and 734 questionnaires could be analyzed. Non-responders showed no systematic differences in diagnosis or treatment. Median age at the time of the interview was 65 (30-91) for responders and 66 (33-96) for non-responders respectively (p = .412). Further analyses were conducted for the 734 responders only. Distribution according to UICC criteria at initial diagnosis was as follows: stage I 46%, stage II 42%, stage III 12%. 78% received breast-preserving surgery, 22% mastectomy. 3% received neo-adjuvant chemotherapy, 85% radiotherapy and 85% anti-hormonal therapy. 49% received adjuvant chemotherapy with taxane containing regimens in 60%. 91% were “satisfied” or “very satisfied” with the surgical result, in which patients with breast-preserving surgery were more satisfied than patients after mastectomy. 66% indicated a complete freedom of pain, 65% reported no limitations of arm or shoulder function. In both cases the results improved with increasing age. In frequency of antihormonal therapy a correspondence of 91% between data from medical records and subjectively reported treatment could be observed. Psychological distress, cognitive limitations and physical consequences were rated on a scale from 1 - “not at all” to 4 - “very much”. The highest average values were found for the items sleep disturbances (2.3) and exhaustion (2.3), the lowest for depression (1.7). Patients up to 60 years suffered more from the psychological consequences than older patients. 44% were in employment before the disease, 66% of them could return to their workplace. The return to work was as easier the younger the patients were. For 75% their partnership did not change, 12% experienced deterioration, 12% improvement. No effect of surgery or systemic treatment could be found here. Before the illness 9% consulted a psychiatrist / psychotherapist, after the illness 19%. Before the diagnosis of breast cancer 14% received antipsychotic drugs, after the disease 26%. In both cases is the increase in frequency stronger for younger patients and for patients who had received chemotherapy. Multivariate analyses will be presented.
Conclusions: Adjuvant breast cancer therapy leads to long lasting impairment of physical, psychological, social and job-related functioning in a significant number of patients. Depending on age, surgery and systemic treatment patients are affected differently.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-08-08.
Collapse
Affiliation(s)
- S Feiten
- Institute for Health Care Research in Oncology, Koblenz, Rhineland-Palatinate, Germany; Breast Cancer Centre Marienhof, Koblenz, Rhineland-Palatinate, Germany; Oncology Group Practice Koblenz, Koblenz, Rhineland-Palatinate, Germany
| | - J Dünnebacke
- Institute for Health Care Research in Oncology, Koblenz, Rhineland-Palatinate, Germany; Breast Cancer Centre Marienhof, Koblenz, Rhineland-Palatinate, Germany; Oncology Group Practice Koblenz, Koblenz, Rhineland-Palatinate, Germany
| | - J Heymanns
- Institute for Health Care Research in Oncology, Koblenz, Rhineland-Palatinate, Germany; Breast Cancer Centre Marienhof, Koblenz, Rhineland-Palatinate, Germany; Oncology Group Practice Koblenz, Koblenz, Rhineland-Palatinate, Germany
| | - H Köppler
- Institute for Health Care Research in Oncology, Koblenz, Rhineland-Palatinate, Germany; Breast Cancer Centre Marienhof, Koblenz, Rhineland-Palatinate, Germany; Oncology Group Practice Koblenz, Koblenz, Rhineland-Palatinate, Germany
| | - J Thomalla
- Institute for Health Care Research in Oncology, Koblenz, Rhineland-Palatinate, Germany; Breast Cancer Centre Marienhof, Koblenz, Rhineland-Palatinate, Germany; Oncology Group Practice Koblenz, Koblenz, Rhineland-Palatinate, Germany
| | - C van Roye
- Institute for Health Care Research in Oncology, Koblenz, Rhineland-Palatinate, Germany; Breast Cancer Centre Marienhof, Koblenz, Rhineland-Palatinate, Germany; Oncology Group Practice Koblenz, Koblenz, Rhineland-Palatinate, Germany
| | - D Wey
- Institute for Health Care Research in Oncology, Koblenz, Rhineland-Palatinate, Germany; Breast Cancer Centre Marienhof, Koblenz, Rhineland-Palatinate, Germany; Oncology Group Practice Koblenz, Koblenz, Rhineland-Palatinate, Germany
| | - R Weide
- Institute for Health Care Research in Oncology, Koblenz, Rhineland-Palatinate, Germany; Breast Cancer Centre Marienhof, Koblenz, Rhineland-Palatinate, Germany; Oncology Group Practice Koblenz, Koblenz, Rhineland-Palatinate, Germany
| |
Collapse
|
21
|
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, Van Roye C, Köppler H. P-157 Routine care reality of patients with myelodysplastic syndromes who received diagnosis and treatment in a community-based oncology group practice in Germany. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70205-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R. Abstract P2-11-11: Patient Reported Outcomes after Breast Cancer Surgery and Adjuvant Therapy from a German Breast Cancer Centre. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-11-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: Evaluation of the subjectively experienced physical, psychological, social and job-related consequences of breast cancer.
Methods: Standardized paper pencil interview of patients with the initial diagnosis of breast cancer who had their primary surgery between 01/2006 and 12/2010 at an accredited breast cancer centre followed by systemic adjuvant treatment. The data collection was conducted with the help of a self-developed scanner-readable questionnaire which had been evaluated in a pretest.
Results: 1260 patients were contacted, 871 completed questionnaires (return rate 72%) were analyzed. Median age of the patients (99.5% women) at the time of the interview was 65 years (30–91). 6% relapsed during the observation period. 91% were “satisfied” or “very satisfied” with the surgical result. 67% indicated a complete freedom of pain. 23% received lymphatic drainage at the time of the questioning (11/2011), 33% complained about limitations of arm and/or shoulder function. 76% received anti-hormonal therapy, 13% stopped the anti-hormonal medication prematurely. Patients received a mean of 1.3 different anti-hormonal therapies, 54% took Tamoxifen. Psychological distress, cognitive limitations and physical consequences were rated on a scale from 1 – “not at all” to 4 – “very much”. The highest average values were found for the items sleep disturbances (2.3) and exhaustion (2.3), the lowest for depression (1.7) and word-finding difficulties (1.8). After therapy only 39% described a complete recovery of their physical capacity, 62% regained their previous mental capacity. 44% were in employment before their disease. 67% returned to their workplace but only 65% of them with their previous number of hours. 15% indicated disadvantages in their workplace due to the breast cancer disease. For 75% their partnership did not change, 12% experienced a deterioration, 13% an improvement. Before the illness 9% consulted a psychiatrist/psychotherapist, after the illness 18%. Before the diagnosis of breast cancer 13% received antipsychotic drugs, after the disease 25%.
Conclusions: Breast cancer diagnosis and therapy leads to long lasting impairment of physical, psychological, social and job-related functioning in a significant number of patients.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-11-11.
Collapse
Affiliation(s)
- S Feiten
- Institute for Health Care Research in Oncology, Koblenz, Germany; Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany; Oncology Group Practice Koblenz, Germany
| | - J Dünnebacke
- Institute for Health Care Research in Oncology, Koblenz, Germany; Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany; Oncology Group Practice Koblenz, Germany
| | - J Heymanns
- Institute for Health Care Research in Oncology, Koblenz, Germany; Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany; Oncology Group Practice Koblenz, Germany
| | - H Köppler
- Institute for Health Care Research in Oncology, Koblenz, Germany; Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany; Oncology Group Practice Koblenz, Germany
| | - J Thomalla
- Institute for Health Care Research in Oncology, Koblenz, Germany; Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany; Oncology Group Practice Koblenz, Germany
| | - C van Roye
- Institute for Health Care Research in Oncology, Koblenz, Germany; Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany; Oncology Group Practice Koblenz, Germany
| | - D Wey
- Institute for Health Care Research in Oncology, Koblenz, Germany; Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany; Oncology Group Practice Koblenz, Germany
| | - R Weide
- Institute for Health Care Research in Oncology, Koblenz, Germany; Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany; Oncology Group Practice Koblenz, Germany
| |
Collapse
|
23
|
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leuk Lymphoma 2012; 54:1640-6. [PMID: 23151046 DOI: 10.3109/10428194.2012.747679] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Bendamustine and bendamustine/rituximab combinations have shown high efficacy in relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent B-cell malignancies (non-Hodgkin lymphoma, NHL). No data exist about bendamustine retreatment after relapse, concerning efficacy and toxicity in this patient population. Eighty-eight outpatients (57 patients with CLL, 31 patients with NHL) who had previously been treated with bendamustine were retreated with a bendamustine regimen. Treatment consisted of bendamustine (B) or bendamustine + mitoxantrone (BM) or bendamustine + rituximab (BR) or bendamustine + mitoxantrone + rituximab (BMR). Median age was 72 years (50-88). A reversible grade 3 or 4 leukocytopenia or thrombocytopenia was observed in 24% and 13%, respectively. The overall response rate (ORR) was 76% (7% complete remission [CR], 69% partial remission [PR]) with 77% (6% CR, 71% PR) in CLL and 71% (8% CR, 63% PR) in NHL. ORR according to regimen was as follows: B: 57% (14% CR, 43% PR), BM: 70% (4% CR, 66% PR), BR: 55% (10% CR, 45% PR), BMR: 84% (7% CR, 78% PR). Bendamustine retreatment is feasible and achieves high response rates and some long lasting remissions.
Collapse
Affiliation(s)
- Rudolf Weide
- Praxisklinik für Hämatologie und Onkologie, Koblenz, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Feiten S, Heymanns J, Köppler H, Thomalla J, van Roye C, Weide R. Subjektiv empfundene Lebensqualität von Patienten unter einer intravenösen Immunglobulinsubstitution und jährliche Kosten der Therapie. Dtsch Med Wochenschr 2012. [DOI: 10.1055/s-0032-1323236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
Weide R, Feiten S, Heymanns J, Thomalla J, van Roye C, Köppler H. Die Behandlung von Patienten mit metastasierten soliden Tumoren in einer onkologischen Schwerpunktpraxis führt zu einem deutlich längeren Gesamtüberleben im Vergleich mit Registerdaten. Dtsch Med Wochenschr 2012. [DOI: 10.1055/s-0032-1323520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|